Commentary|Articles|November 5, 2024

Rethinking Diabetes Care: Are New Therapies Adding Value or Cost?

Sanjula Jain, PhD, chief research officer at Trilliant Health, discusses the rapid adoption of glucagon-like peptide 1 inhibitors for diabetes and preventive care for obesity and late-onset diabetes.

The latest report from Trilliant Health examined both the rapid adoption of glucagon-like peptide 1 (GLP-1) inhibitors for diabetes management and the broader challenges the US health care system faces in preventive care.